Travere Therapeutics announced that Sandra Calvin will retire as chief accounting officer and principal accounting officer, with John Torell expected to succeed her to facilitate an orderly transition.
| IndividualSandra CalvinJohn Torell, CFA, CPA | RoleChief Accounting Officer; Principal Accounting OfficerVice President, Controller; expected to be appointed Chief Accounting Officer and Principal Accounting Officer | Type of ChangeRetirement (announced)Succession / Appointment (expected) | Effective DateFollowing filing of 2026 Annual Report on Form 10-K (expected February 2027)Expected to be appointed in advance of the Retirement Date (to facilitate transition) | ReasonRetirementPlanned succession to facilitate orderly transition | Replacement InfoSuccessor expected to be John TorellN/A | Background DetailsNot disclosedJoined Travere in 2021; responsible for accounting operations, financial & SEC reporting, technical accounting, and internal controls; VP, Controller since 2023; prior roles at Pacific Life (1997–2019) and Audit Manager at Deloitte; CFA, CPA; B.A. Economics-Business, UCLA | Board/Committee Role ChangesNot disclosedNot disclosed |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.